Form 8-K - Current report:
SEC Accession No. 0001601485-25-000046
Filing Date
2025-03-31
Accepted
2025-03-31 07:01:52
Documents
21
Period of Report
2025-03-31
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K angn-20250331.htm   iXBRL 8-K 24293
2 EX-99.1 q42024earningspr.htm EX-99.1 6519
6 q42024earningspr001.jpg GRAPHIC 123411
7 q42024earningspr002.jpg GRAPHIC 168255
8 q42024earningspr003.jpg GRAPHIC 111961
9 q42024earningspr004.jpg GRAPHIC 141905
10 q42024earningspr005.jpg GRAPHIC 154739
11 q42024earningspr006.jpg GRAPHIC 170359
12 q42024earningspr007.jpg GRAPHIC 41464
  Complete submission text file 0001601485-25-000046.txt   1417957

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT angn-20250331.xsd EX-101.SCH 1870
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT angn-20250331_lab.xml EX-101.LAB 22786
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT angn-20250331_pre.xml EX-101.PRE 13130
24 EXTRACTED XBRL INSTANCE DOCUMENT angn-20250331_htm.xml XML 2907
Mailing Address 451 D STREET, 5TH FLOOR BOSTON MA 02210
Business Address 451 D STREET, 5TH FLOOR BOSTON MA 02210 (857) 209-0050
Elicio Therapeutics, Inc. (Filer) CIK: 0001601485 (see all company filings)

EIN.: 113430072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39990 | Film No.: 25788804
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)